Circulating Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in 11C Choline-identified Oligometastatic Castration-Refractory Prostate Cancer Treated with Stereotactic Ablative Radiotherapy

Stereotactic ablative radiotherapy (SABR) has demonstrated clinical benefit in oligometastatic prostate cancer patients. However, the risk of developing new distant metastatic lesions remains high and only a minority of patients experience durable progression-free response. Therefore, there is a critical need to identify which subset of oligometastatic patients will benefit from SABR alone versus combination SABR and systemic agents. Herein, we provide the first proof-of-concept for the clinical value of circulating prostate cancer-specific extracellular vesicles (PCEVs) as non-invasive predictor of oncological outcomes in oligometastatic castration-refractory prostate cancer (oCRPC) patients treated with SABR. We have defined PCEVs and analyzed their kinetics in the peripheral blood of 79 oCRPC patients with nanoscale flow cytometry at baseline and days 1, 7, and 14 post-SABR. High PCEV levels at baseline was predictive of shorter time to distant recurrence (3.5 vs 6.6 months, p=0.0087). Following SABR, PCEV levels reached a peak at day 7 and median overall survival was significantly longer in patients with higher PCEV levels (32.7 vs 27.6 months, p=0.003). This suggests that pre-treatment PCEV levels can be a biomarker of tumor burden while early changes post-treatment can predict response to SABR. In contrast, radiomic analyses of 11C-choline PET/CT before and after SABR was not predictive of clinical outcomes. Interestingly, a correlation was noted between PCEV levels and peripheral tumor-reactive CD8 T cells (TTR; CD8+ CD11ahigh). This original study demonstrates that circulating PCEVs can serve as prognostic and predictive marker to SABR in order to identify true oCRPC patients. In addition, we provide novel insights in the global crosstalk mediated by PCEVs between tumors and immune cells which leads to systemic suppression of immunity against CRPC. This work lays the foundation for future studies that investigate the underpinnings of metastatic progression and providing new therapeutic targets (e.g PCEVs) to improve SABR efficacy and clinical outcomes in treatment resistant CRPC.

[1]  M. Balancin,et al.  Pulmonary Neuroendocrine Neoplasms Overexpressing Epithelial-Mesenchymal Transition Mechanical Barriers Genes Lack Immune-Suppressive Response and Present an Increased Risk of Metastasis , 2021, Frontiers in Oncology.

[2]  J. Yaxley,et al.  Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review , 2021, Advances in urology.

[3]  Yohan Kim,et al.  Abstract 675: Radiotherapy inhibits the antitumor immune response through release of immunosuppressive tumor-derived extracellular vesicles in prostate cancer , 2021, Clinical Research (Excluding Clinical Trials).

[4]  K. Rahbar,et al.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.

[5]  S. Tyldesley,et al.  Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care , 2021, Current oncology.

[6]  Q. Tan,et al.  Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy , 2021, EBioMedicine.

[7]  P. Troncoso,et al.  Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment , 2021, Clinical Cancer Research.

[8]  C. Morrison,et al.  T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors , 2021, Nature Communications.

[9]  A. Torbicki,et al.  Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension , 2021, Journal of clinical medicine.

[10]  H. Leong,et al.  Clinical significance of STEAP1 extracellular vesicles in prostate cancer , 2021, Prostate Cancer and Prostatic Diseases.

[11]  S. Keevil,et al.  Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. , 2021, The Lancet. Oncology.

[12]  Yohan Kim,et al.  Leukemic Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  S. Sleijfer,et al.  Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer , 2020, BMC cancer.

[14]  R. McWilliams,et al.  Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients , 2020, Melanoma research.

[15]  A. Abdollahi,et al.  Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature , 2020, Cancer Immunology, Immunotherapy.

[16]  F. Furnari,et al.  Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas , 2020, EBioMedicine.

[17]  D. Ledbetter,et al.  Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention , 2020, Science.

[18]  Wanzun Lin,et al.  Radiation-induced small extracellular vesicles as “carriages” promote tumor antigen release and trigger antitumor immunity , 2020, Theranostics.

[19]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[20]  L. Klotz,et al.  Expression of Small Non-coding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. , 2020, The Journal of urology.

[21]  L. Badimón,et al.  The Mediterranean diet decreases prothrombotic microvesicle release in asymptomatic individuals at high cardiovascular risk. , 2020, Clinical nutrition.

[22]  Aaron J. Johnson,et al.  The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. , 2020, Neuro-oncology.

[23]  E. Goetghebeur,et al.  Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. , 2020 .

[24]  S. Demaria,et al.  CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection , 2020, Cancer Immunology Research.

[25]  Leonie L. Zeune,et al.  Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival , 2020, British Journal of Cancer.

[26]  R. Nieuwland,et al.  Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction , 2018, Platelets.

[27]  Serge K. Lyashchenko,et al.  Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody , 2019, The Journal of Nuclear Medicine.

[28]  D. Murphy,et al.  Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. , 2019, European urology oncology.

[29]  Wei Yang,et al.  Comprehensive palmitoyl-proteomic analysis identifies distinct protein signatures for large and small cancer-derived extracellular vesicles , 2019, bioRxiv.

[30]  J. Carles,et al.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[31]  M. Loda,et al.  The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance , 2019, Clinical Cancer Research.

[32]  Joel Nothman,et al.  SciPy 1.0-Fundamental Algorithms for Scientific Computing in Python , 2019, ArXiv.

[33]  C. Brinker,et al.  Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma , 2019, The Prostate.

[34]  R. Blelloch,et al.  Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory , 2019, Cell.

[35]  R. Epstein,et al.  Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA‐617 Therapy for Metastatic Castration‐Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression , 2019, Clinical genitourinary cancer.

[36]  G. Cheon,et al.  Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. , 2019, Endocrine-related cancer.

[37]  Sean S. Park,et al.  Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. , 2019, International journal of radiation oncology, biology, physics.

[38]  P. Carroll,et al.  A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. , 2018, European urology.

[39]  L. Mariani,et al.  Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma , 2018, The Journal of clinical investigation.

[40]  R. Emerson,et al.  Radiotherapy induces responses of lung cancer to CTLA-4 blockade , 2018, Nature Medicine.

[41]  Wei Zhang,et al.  Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response , 2018, Nature.

[42]  B. Ueberheide,et al.  Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs , 2018, Cancer Immunology Research.

[43]  Hakho Lee,et al.  Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles , 2018, Science Advances.

[44]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Clayton,et al.  Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes , 2017, Journal of extracellular vesicles.

[46]  G. Jenster,et al.  The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. , 2017, European urology.

[47]  R. Miralbell,et al.  Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[48]  Sean S. Park,et al.  T cell Bim levels reflect responses to anti-PD-1 cancer therapy. , 2016, JCI insight.

[49]  Bing Wang,et al.  Exosome-mediated microRNA transfer plays a role in radiation-induced bystander effect , 2015, RNA biology.

[50]  Sean S. Park,et al.  PD-1 Restrains Radiotherapy-Induced Abscopal Effect , 2015, Cancer Immunology Research.

[51]  L. Mincheva-Nilsson,et al.  Prostate Tumor-Derived Exosomes Down-Regulate NKG2D Expression on Natural Killer Cells and CD8+ T Cells: Mechanism of Immune Evasion , 2014, PloS one.

[52]  N. Lumen,et al.  Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial , 2014, BMC Cancer.

[53]  M. V. van Gemert,et al.  Single vs. swarm detection of microparticles and exosomes by flow cytometry , 2012, Journal of thrombosis and haemostasis : JTH.

[54]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[55]  M. Mason,et al.  Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production , 2011, The Journal of Immunology.

[56]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[57]  Tjerk P. Straatsma,et al.  NWChem: A comprehensive and scalable open-source solution for large scale molecular simulations , 2010, Comput. Phys. Commun..

[58]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[59]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  B. Suffoletto,et al.  Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  K. Nikolaou,et al.  Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.